• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

Global and China Urological Cancer Therapeutics Drugs Market Insights, Forecast to 2026

report cover
  • 3 September 2020
  • Healthcare
  • 148 Pages
  • Report Code: 24LS-21402
  • Formate :   
Download FREE Report Sample Download PDF File

Urological Cancer Therapeutics Drugs -MARKET ADVISORY SERVICES

Urological Cancer Therapeutics Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Urological Cancer Therapeutics Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Urological Cancer Therapeutics Drugs market is segmented into
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)

Segment by Application, the Urological Cancer Therapeutics Drugs market is segmented into
Hospital
Medical Research Laboratory
Others

Regional and Country-level Analysis
The Urological Cancer Therapeutics Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Urological Cancer Therapeutics Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Urological Cancer Therapeutics Drugs Market Share Analysis
Urological Cancer Therapeutics Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Urological Cancer Therapeutics Drugs business, the date to enter into the Urological Cancer Therapeutics Drugs market, Urological Cancer Therapeutics Drugs product introduction, recent developments, etc.
The major vendors covered:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
1 Study Coverage
1.1 Urological Cancer Therapeutics Drugs Product Introduction
1.2 Market Segments
1.3 Key Urological Cancer Therapeutics Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type
1.4.2 Xofigo (radium Ra 223 dichloride)
1.4.3 Jevtana (cabazitaxel)
1.4.4 Inlyta (axitinib)
1.4.5 Votrient (pazopanib hydrochloride)
1.4.6 Sutent (sunitinib malate)
1.4.7 Zytiga (abiraterone acetate)
1.4.8 Xtandi (enzalutamide)
1.4.9 Opdivo (nivolumab)
1.4.10 Provenge (sipuleucel-T)
1.5 Market by Application
1.5.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Medical Research Laboratory
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Urological Cancer Therapeutics Drugs Market Size, Estimates and Forecasts
2.1.1 Global Urological Cancer Therapeutics Drugs Revenue 2015-2026
2.1.2 Global Urological Cancer Therapeutics Drugs Sales 2015-2026
2.2 Global Urological Cancer Therapeutics Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Urological Cancer Therapeutics Drugs Historical Market Size by Region (2015-2020)
2.3.1 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Urological Cancer Therapeutics Drugs Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Region (2021-2026)
2.4.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2021-2026)

3 Global Urological Cancer Therapeutics Drugs Competitor Landscape by Players
3.1 Global Top Urological Cancer Therapeutics Drugs Sales by Manufacturers
3.1.1 Global Urological Cancer Therapeutics Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Urological Cancer Therapeutics Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Global Urological Cancer Therapeutics Drugs Manufacturers by Revenue
3.2.1 Global Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Urological Cancer Therapeutics Drugs Revenue in 2019
3.2.5 Global Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Urological Cancer Therapeutics Drugs Price by Manufacturers
3.4 Global Urological Cancer Therapeutics Drugs Manufacturing Base Distribution, Product Types
3.4.1 Urological Cancer Therapeutics Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Urological Cancer Therapeutics Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
4.1.1 Global Urological Cancer Therapeutics Drugs Sales by Type (2015-2020)
4.1.2 Global Urological Cancer Therapeutics Drugs Revenue by Type (2015-2020)
4.1.3 Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Urological Cancer Therapeutics Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Urological Cancer Therapeutics Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Urological Cancer Therapeutics Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
5.1.1 Global Urological Cancer Therapeutics Drugs Sales by Application (2015-2020)
5.1.2 Global Urological Cancer Therapeutics Drugs Revenue by Application (2015-2020)
5.1.3 Urological Cancer Therapeutics Drugs Price by Application (2015-2020)
5.2 Urological Cancer Therapeutics Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Urological Cancer Therapeutics Drugs Price Forecast by Application (2021-2026)

6 China by Players, Type and Application
6.1 China Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
6.1.1 China Urological Cancer Therapeutics Drugs Sales YoY Growth 2015-2026
6.1.2 China Urological Cancer Therapeutics Drugs Revenue YoY Growth 2015-2026
6.1.3 China Urological Cancer Therapeutics Drugs Market Share in Global Market 2015-2026
6.2 China Urological Cancer Therapeutics Drugs Market Size by Players (International and Local Players)
6.2.1 China Top Urological Cancer Therapeutics Drugs Players by Sales (2015-2020)
6.2.2 China Top Urological Cancer Therapeutics Drugs Players by Revenue (2015-2020)
6.3 China Urological Cancer Therapeutics Drugs Historic Market Review by Type (2015-2020)
6.3.1 China Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
6.3.2 China Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2015-2020)
6.3.3 China Urological Cancer Therapeutics Drugs Price by Type (2015-2020)
6.4 China Urological Cancer Therapeutics Drugs Market Estimates and Forecasts by Type (2021-2026)
6.4.1 China Urological Cancer Therapeutics Drugs Sales Forecast by Type (2021-2026)
6.4.2 China Urological Cancer Therapeutics Drugs Revenue Forecast by Type (2021-2026)
6.4.3 China Urological Cancer Therapeutics Drugs Price Forecast by Type (2021-2026)
6.5 China Urological Cancer Therapeutics Drugs Historic Market Review by Application (2015-2020)
6.5.1 China Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
6.5.2 China Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2015-2020)
6.5.3 China Urological Cancer Therapeutics Drugs Price by Application (2015-2020)
6.6 China Urological Cancer Therapeutics Drugs Market Estimates and Forecasts by Application (2021-2026)
6.6.1 China Urological Cancer Therapeutics Drugs Sales Forecast by Application (2021-2026)
6.6.2 China Urological Cancer Therapeutics Drugs Revenue Forecast by Application (2021-2026)
6.6.3 China Urological Cancer Therapeutics Drugs Price Forecast by Application (2021-2026)

7 North America
7.1 North America Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
7.2 North America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
7.2.1 North America Urological Cancer Therapeutics Drugs Sales by Country (2015-2020)
7.2.2 North America Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada

8 Europe
8.1 Europe Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
8.2 Europe Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
8.2.1 Europe Urological Cancer Therapeutics Drugs Sales by Country
8.2.2 Europe Urological Cancer Therapeutics Drugs Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia

9 Asia Pacific
9.1 Asia Pacific Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
9.2 Asia Pacific Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
9.2.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region (2015-2020)
9.2.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam

10 Latin America
10.1 Latin America Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
10.2 Latin America Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
10.2.1 Latin America Urological Cancer Therapeutics Drugs Sales by Country
10.2.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina

11 Middle East and Africa
11.1 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Urological Cancer Therapeutics Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country
11.2.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E

12 Company Profiles
12.1 Novartis
12.1.1 Novartis Corporation Information
12.1.2 Novartis Description and Business Overview
12.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
12.1.5 Novartis Recent Development
12.2 Pfizer
12.2.1 Pfizer Corporation Information
12.2.2 Pfizer Description and Business Overview
12.2.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Pfizer Urological Cancer Therapeutics Drugs Products Offered
12.2.5 Pfizer Recent Development
12.3 Johnson & Johnson
12.3.1 Johnson & Johnson Corporation Information
12.3.2 Johnson & Johnson Description and Business Overview
12.3.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Products Offered
12.3.5 Johnson & Johnson Recent Development
12.4 AstraZeneca
12.4.1 AstraZeneca Corporation Information
12.4.2 AstraZeneca Description and Business Overview
12.4.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
12.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Products Offered
12.4.5 AstraZeneca Recent Development
12.5 Astellas
12.5.1 Astellas Corporation Information
12.5.2 Astellas Description and Business Overview
12.5.3 Astellas Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Astellas Urological Cancer Therapeutics Drugs Products Offered
12.5.5 Astellas Recent Development
12.6 Bristol-Myers Squibb
12.6.1 Bristol-Myers Squibb Corporation Information
12.6.2 Bristol-Myers Squibb Description and Business Overview
12.6.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products Offered
12.6.5 Bristol-Myers Squibb Recent Development
12.7 Abbott Laboratories
12.7.1 Abbott Laboratories Corporation Information
12.7.2 Abbott Laboratories Description and Business Overview
12.7.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Products Offered
12.7.5 Abbott Laboratories Recent Development
12.8 Celgene Corporation
12.8.1 Celgene Corporation Corporation Information
12.8.2 Celgene Corporation Description and Business Overview
12.8.3 Celgene Corporation Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Products Offered
12.8.5 Celgene Corporation Recent Development
12.9 Dendreon Corporation
12.9.1 Dendreon Corporation Corporation Information
12.9.2 Dendreon Corporation Description and Business Overview
12.9.3 Dendreon Corporation Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Products Offered
12.9.5 Dendreon Corporation Recent Development
12.10 Ferring Pharmaceuticals
12.10.1 Ferring Pharmaceuticals Corporation Information
12.10.2 Ferring Pharmaceuticals Description and Business Overview
12.10.3 Ferring Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products Offered
12.10.5 Ferring Pharmaceuticals Recent Development
12.11 Novartis
12.11.1 Novartis Corporation Information
12.11.2 Novartis Description and Business Overview
12.11.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
12.11.5 Novartis Recent Development
12.12 Indevus Pharmaceuticals Inc
12.12.1 Indevus Pharmaceuticals Inc Corporation Information
12.12.2 Indevus Pharmaceuticals Inc Description and Business Overview
12.12.3 Indevus Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Indevus Pharmaceuticals Inc Products Offered
12.12.5 Indevus Pharmaceuticals Inc Recent Development
12.13 Ipsen
12.13.1 Ipsen Corporation Information
12.13.2 Ipsen Description and Business Overview
12.13.3 Ipsen Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Ipsen Products Offered
12.13.5 Ipsen Recent Development
12.14 Roche Healthcare
12.14.1 Roche Healthcare Corporation Information
12.14.2 Roche Healthcare Description and Business Overview
12.14.3 Roche Healthcare Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Roche Healthcare Products Offered
12.14.5 Roche Healthcare Recent Development
12.15 Sanofi S.A.
12.15.1 Sanofi S.A. Corporation Information
12.15.2 Sanofi S.A. Description and Business Overview
12.15.3 Sanofi S.A. Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Sanofi S.A. Products Offered
12.15.5 Sanofi S.A. Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Urological Cancer Therapeutics Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Urological Cancer Therapeutics Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables

Table 1. Urological Cancer Therapeutics Drugs Market Segments

Table 2. Ranking of Global Top Urological Cancer Therapeutics Drugs Manufacturers by Revenue (US$ Million) in 2019

Table 3. Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)

Table 4. Major Manufacturers of Xofigo (radium Ra 223 dichloride)

Table 5. Major Manufacturers of Jevtana (cabazitaxel)

Table 6. Major Manufacturers of Inlyta (axitinib)

Table 7. Major Manufacturers of Votrient (pazopanib hydrochloride)

Table 8. Major Manufacturers of Sutent (sunitinib malate)

Table 9. Major Manufacturers of Zytiga (abiraterone acetate)

Table 10. Major Manufacturers of Xtandi (enzalutamide)

Table 11. Major Manufacturers of Opdivo (nivolumab)

Table 12. Major Manufacturers of Provenge (sipuleucel-T)

Table 13. Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Application 2020-2026 (K MT)

Table 14. Global Urological Cancer Therapeutics Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026

Table 15. Global Urological Cancer Therapeutics Drugs Sales by Regions 2015-2020 (K MT)

Table 16. Global Urological Cancer Therapeutics Drugs Sales Market Share by Regions (2015-2020)

Table 17. Global Urological Cancer Therapeutics Drugs Revenue by Regions 2015-2020 (US$ Million)

Table 18. Global Urological Cancer Therapeutics Drugs Sales Forecast by Region (2021-2026) (K MT)

Table 19. Global Urological Cancer Therapeutics Drugs Sales by Manufacturers (2015-2020) (K MT)

Table 20. Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturers (2015-2020)

Table 21. Global Urological Cancer Therapeutics Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)

Table 22. Global Urological Cancer Therapeutics Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2019)

Table 23. Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2015-2020) (US$ Million)

Table 24. Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2015-2020)

Table 25. Key Manufacturers Urological Cancer Therapeutics Drugs Price (2015-2020) (USD/MT)

Table 26. Urological Cancer Therapeutics Drugs Manufacturers Manufacturing Base Distribution and Headquarters

Table 27. Manufacturers Urological Cancer Therapeutics Drugs Product Type

Table 28. Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market

Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 30. Global Urological Cancer Therapeutics Drugs Sales by Type (2015-2020) (K MT)

Table 31. Global Urological Cancer Therapeutics Drugs Sales Share by Type (2015-2020)

Table 32. Global Urological Cancer Therapeutics Drugs Revenue by Type (2015-2020) (US$ Million)

Table 33. Global Urological Cancer Therapeutics Drugs Revenue Share by Type (2015-2020)

Table 34. Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)

Table 35. Global Urological Cancer Therapeutics Drugs Sales Share by Type (2021-2026)

Table 36. Global Urological Cancer Therapeutics Drugs Sales by Application (2015-2020) (K MT)

Table 37. Global Urological Cancer Therapeutics Drugs Sales Share by Application (2015-2020)

Table 38. Global Urological Cancer Therapeutics Drugs Sales Share by Application (2021-2026)

Table 39. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Application (2021-2026)

Table 40. Global Urological Cancer Therapeutics Drugs Revenue by Application (2015-2020) (US$ Million)

Table 41. Global Urological Cancer Therapeutics Drugs Revenue Market Share Forecast by Application (2021-2026)

Table 42. China Urological Cancer Therapeutics Drugs Sales (K MT) of Key Companies (2015-2020)

Table 43. China Urological Cancer Therapeutics Drugs Sales Share by Company (2015-2020)

Table 44. China Urological Cancer Therapeutics Drugs Revenue (US$ Million) by Company (2015-2020)

Table 45. China Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2015-2020)

Table 46. China Urological Cancer Therapeutics Drugs Sales Share by Type (2015-2020)

Table 47. China Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Type (2015-2020)

Table 48. China Urological Cancer Therapeutics Drugs Price (K MT) by Type (2015-2020)

Table 49. China Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2021-2026)

Table 50. China Urological Cancer Therapeutics Drugs Sales Share by Type (2021-2026)

Table 51. China Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Type (2021-2026)

Table 52. China Urological Cancer Therapeutics Drugs Revenue Share by Type (2021-2026)

Table 53. China Urological Cancer Therapeutics Drugs Price (K MT) by Type (2021-2026)

Table 54. China Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2015-2020)

Table 55. China Urological Cancer Therapeutics Drugs Sales Share by Application (2015-2020)

Table 56. China Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Application (2015-2020)

Table 57. China Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2021-2026)

Table 58. China Urological Cancer Therapeutics Drugs Sales Share by Application (2021-2026)

Table 59. China Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Application (2021-2026)

Table 60. China Urological Cancer Therapeutics Drugs Revenue Share by Application (2021-2026)

Table 61. North America Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)

Table 62. North America Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)

Table 63. North America Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)

Table 64. North America Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)

Table 65. Europe Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)

Table 66. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)

Table 67. Europe Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)

Table 68. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)

Table 69. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region (2015-2020) (K MT)

Table 70. Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)

Table 71. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region (2015-2020) (US$ Million)

Table 72. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2015-2020)

Table 73. Latin America Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)

Table 74. Latin America Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)

Table 75. Latin Americaa Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)

Table 76. Latin America Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)

Table 77. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country (2015-2020) (K MT)

Table 78. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country (2015-2020)

Table 79. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country (2015-2020) (US$ Million)

Table 80. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2015-2020)

Table 81. Novartis Corporation Information

Table 82. Novartis Description and Business Overview

Table 83. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 84. Novartis Urological Cancer Therapeutics Drugs Product

Table 85. Novartis Recent Development

Table 86. Pfizer Corporation Information

Table 87. Pfizer Description and Business Overview

Table 88. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 89. Pfizer Product

Table 90. Pfizer Recent Development

Table 91. Johnson & Johnson Corporation Information

Table 92. Johnson & Johnson Description and Business Overview

Table 93. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 94. Johnson & Johnson Product

Table 95. Johnson & Johnson Recent Development

Table 96. AstraZeneca Corporation Information

Table 97. AstraZeneca Description and Business Overview

Table 98. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 99. AstraZeneca Product

Table 100. AstraZeneca Recent Development

Table 101. Astellas Corporation Information

Table 102. Astellas Description and Business Overview

Table 103. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 104. Astellas Product

Table 105. Astellas Recent Development

Table 106. Bristol-Myers Squibb Corporation Information

Table 107. Bristol-Myers Squibb Description and Business Overview

Table 108. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 109. Bristol-Myers Squibb Product

Table 110. Bristol-Myers Squibb Recent Development

Table 111. Abbott Laboratories Corporation Information

Table 112. Abbott Laboratories Description and Business Overview

Table 113. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 114. Abbott Laboratories Product

Table 115. Abbott Laboratories Recent Development

Table 116. Celgene Corporation Corporation Information

Table 117. Celgene Corporation Description and Business Overview

Table 118. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 119. Celgene Corporation Product

Table 120. Celgene Corporation Recent Development

Table 121. Dendreon Corporation Corporation Information

Table 122. Dendreon Corporation Description and Business Overview

Table 123. Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 124. Dendreon Corporation Product

Table 125. Dendreon Corporation Recent Development

Table 126. Ferring Pharmaceuticals Corporation Information

Table 127. Ferring Pharmaceuticals Description and Business Overview

Table 128. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 129. Ferring Pharmaceuticals Product

Table 130. Ferring Pharmaceuticals Recent Development

Table 131. GlaxoSmithKline plc Corporation Information

Table 132. GlaxoSmithKline plc Description and Business Overview

Table 133. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 134. GlaxoSmithKline plc Product

Table 135. GlaxoSmithKline plc Recent Development

Table 136. Indevus Pharmaceuticals Inc Corporation Information

Table 137. Indevus Pharmaceuticals Inc Description and Business Overview

Table 138. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 139. Indevus Pharmaceuticals Inc Product

Table 140. Indevus Pharmaceuticals Inc Recent Development

Table 141. Ipsen Corporation Information

Table 142. Ipsen Description and Business Overview

Table 143. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 144. Ipsen Product

Table 145. Ipsen Recent Development

Table 146. Roche Healthcare Corporation Information

Table 147. Roche Healthcare Description and Business Overview

Table 148. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 149. Roche Healthcare Product

Table 150. Roche Healthcare Recent Development

Table 151. Sanofi S.A. Corporation Information

Table 152. Sanofi S.A. Description and Business Overview

Table 153. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)

Table 154. Sanofi S.A. Product

Table 155. Sanofi S.A. Recent Development

Table 156. Key Opportunities and Drivers: Impact Analysis (2021-2026)

Table 157. Key Challenges

Table 158. Market Risks

Table 159. Main Points Interviewed from Key Urological Cancer Therapeutics Drugs Players

Table 160. Urological Cancer Therapeutics Drugs Customers List

Table 161. Urological Cancer Therapeutics Drugs Distributors List

Table 162. Research Programs/Design for This Report

Table 163. Key Data Information from Secondary Sources

Table 164. Key Data Information from Primary Sources

List of Figures

Figure 1. Urological Cancer Therapeutics Drugs Product Picture

Figure 2. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2020 & 2026

Figure 3. Xofigo (radium Ra 223 dichloride) Product Picture

Figure 4. Jevtana (cabazitaxel) Product Picture

Figure 5. Inlyta (axitinib) Product Picture

Figure 6. Votrient (pazopanib hydrochloride) Product Picture

Figure 7. Sutent (sunitinib malate) Product Picture

Figure 8. Zytiga (abiraterone acetate) Product Picture

Figure 9. Xtandi (enzalutamide) Product Picture

Figure 10. Opdivo (nivolumab) Product Picture

Figure 11. Provenge (sipuleucel-T) Product Picture

Figure 12. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application in 2020 & 2026

Figure 13. Hospital

Figure 14. Medical Research Laboratory

Figure 15. Others

Figure 16. Urological Cancer Therapeutics Drugs Report Years Considered

Figure 17. Global Urological Cancer Therapeutics Drugs Market Size 2015-2026 (US$ Million)

Figure 18. Global Urological Cancer Therapeutics Drugs Sales 2015-2026 (K MT)

Figure 19. Global Urological Cancer Therapeutics Drugs Market Size Market Share by Region: 2020 Versus 2026

Figure 20. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)

Figure 21. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region in 2019

Figure 22. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2015-2020)

Figure 23. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region in 2019

Figure 24. Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturer in 2019

Figure 25. The Top 10 and 5 Players Market Share by Urological Cancer Therapeutics Drugs Revenue in 2019

Figure 26. Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019

Figure 27. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)

Figure 28. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2019

Figure 29. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2015-2020)

Figure 30. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type in 2019

Figure 31. Global Urological Cancer Therapeutics Drugs Market Share by Price Range (2015-2020)

Figure 32. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)

Figure 33. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application in 2019

Figure 34. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2015-2020)

Figure 35. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application in 2019

Figure 36. China Urological Cancer Therapeutics Drugs Sales Growth Rate 2015-2026 (K MT)

Figure 37. China Urological Cancer Therapeutics Drugs Revenue Growth Rate 2015-2026 (US$ Million)

Figure 38. China Urological Cancer Therapeutics Drugs Market Share in Global Market 2015-2026

Figure 39. China 5 and 10 Largest Urological Cancer Therapeutics Drugs Players Market Share by Revenue in Urological Cancer Therapeutics Drugs in 2019

Figure 40. China Urological Cancer Therapeutics Drugs Revenue Share by Type (2015-2020)

Figure 41. China Urological Cancer Therapeutics Drugs Revenue Growth Rate by Type in 2015 & 2019

Figure 42. China Urological Cancer Therapeutics Drugs Revenue Share by Application (2015-2020)

Figure 43. China Urological Cancer Therapeutics Drugs Revenue Growth Rate by Application in 2015 & 2019

Figure 44. North America Urological Cancer Therapeutics Drugs Sales Growth Rate 2015-2020 (K MT)

Figure 45. North America Urological Cancer Therapeutics Drugs Revenue Growth Rate 2015-2020 (US$ Million)

Figure 46. North America Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019

Figure 47. North America Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019

Figure 48. U.S. Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 49. U.S. Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 50. Canada Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 51. Canada Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 52. Europe Urological Cancer Therapeutics Drugs Sales Growth Rate 2015-2020 (K MT)

Figure 53. Europe Urological Cancer Therapeutics Drugs Revenue Growth Rate 2015-2020 (US$ Million)

Figure 54. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019

Figure 55. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019

Figure 56. Germany Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 57. Germany Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 58. France Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 59. France Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 60. U.K. Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 61. U.K. Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 62. Italy Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 63. Italy Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 64. Russia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 65. Russia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 66. Asia Pacific Urological Cancer Therapeutics Drugs Sales Growth Rate 2015-2020 (K MT)

Figure 67. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Growth Rate 2015-2020 (US$ Million)

Figure 68. Asia Pacific Urological Cancer Therapeutics Drugs Sales Market Share by Region in 2019

Figure 69. Asia Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Region in 2019

Figure 70. China Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 71. China Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 72. Japan Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 73. Japan Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 74. South Korea Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 75. South Korea Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 76. India Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 77. India Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 78. Australia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 79. Australia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 80. Taiwan Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 81. Taiwan Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 82. Indonesia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 83. Indonesia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 84. Thailand Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 85. Thailand Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 86. Malaysia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 87. Malaysia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 88. Philippines Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 89. Philippines Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 90. Vietnam Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 91. Vietnam Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 92. Latin America Urological Cancer Therapeutics Drugs Sales Growth Rate 2015-2020 (K MT)

Figure 93. Latin America Urological Cancer Therapeutics Drugs Revenue Growth Rate 2015-2020 (US$ Million)

Figure 94. Latin America Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019

Figure 95. Latin America Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019

Figure 96. Mexico Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 97. Mexico Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 98. Brazil Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 99. Brazil Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 100. Argentina Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 101. Argentina Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 102. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Growth Rate 2015-2020 (K MT)

Figure 103. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Growth Rate 2015-2020 (US$ Million)

Figure 104. Middle East and Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2019

Figure 105. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2019

Figure 106. Turkey Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 107. Turkey Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 108. Saudi Arabia Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 109. Saudi Arabia Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 110. U.A.E Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2020) (K MT)

Figure 111. U.A.E Urological Cancer Therapeutics Drugs Revenue Growth Rate (2015-2020) (US$ Million)

Figure 112. Porter's Five Forces Analysis

Figure 113. Urological Cancer Therapeutics Drugs Value Chain

Figure 114. Channels of Distribution

Figure 115. Distributors Profiles

Figure 116. Bottom-up and Top-down Approaches for This Report

Figure 117. Data Triangulation

Figure 118. Key Executives Interviewed

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline plc

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A.

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $3081

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase